FLT3 and acute myeloid leukemia: This study demonstrated a statistically significant overall survival benefit with quizartinib in patients with relapsed/refractory FLT3-ITD–positive AML versus salvage chemotherapy, with a 24% reduction in the risk of death during the observation period.